Cancer Research Cell Death Mechanisms and Cancer Therapy Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Toyooka, S.
Right arrow Articles by Gazdar, A. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Toyooka, S.
Right arrow Articles by Gazdar, A. F.
[Cancer Research 62, 3382-3386, June 15, 2002]
© 2002 American Association for Cancer Research

Advances in Brief

Aberrant Methylation of the CDH13 (H-cadherin) Promoter Region in Colorectal Cancers and Adenomas1

Shinichi Toyooka, Kiyomi O. Toyooka, Kenichi Harada, Kuniharu Miyajima, Prakash Makarla, Ubaradka G. Sathyanarayana, Jing Yin, Fumiaki Sato, Narayan Shivapurkar, Stephen J. Meltzer and Adi F. Gazdar2

Hamon Center for Therapeutic Oncology Research [S. T., K. O. T., K. H., K. M., P. M., U. G. S., N. S., A. F. G.] and Department of Pathology [P. M., U. G. S., N. S., A. F. G.], University of Texas Southwestern Medical Center, Dallas, Texas 75390, and Department of Medicine (Gastroenterology Division), Greenebaum Cancer Center, University of Maryland School of Medicine and Baltimore Veterans Affairs Hospital, Baltimore, Maryland 21201 [J. Y., F. S., S. J. M.]

Expression of the cadherin family member CDH13 (H-cadherin) is reduced in several human tumors, and it has been hypothesized that this gene functions as a tumor suppressor gene. Previously, we reported that the 5' region of CDH13 is frequently methylated in breast and lung cancers. Here we confirmed the promoter activity of 5' region of CDH13 by luciferase assay and examined its aberrant methylation in colorectal cancers, cell lines, and adenomas. Methylation status was investigated by methylation-specific PCR (MSP) and by bisulfite DNA sequencing of cloned DNA of PCR amplicons. In cell lines, we examined the correlation between methylation status and mRNA expression by reverse transcription-PCR. Aberrant methylation of CDH13 was present in 7 of 13 (54%) cell lines, and expression was absent in 6 of 13 (46%) cell lines. CDH13 expression was present in six cell lines that showed only the unmethylated form by MSP and in one cell line that showed both the methylated and unmethylated forms. Treatment with 5-aza-2'-deoxycytidine restored CDH13 expression in methylated cell lines. In surgically resected samples, 17 of 35 (49%) cases of primary colorectal cancer, 2 of 33 (6%) cases of corresponding nonmalignant colorectal mucosa, and 8 of 19 (42%) adenomas were methylated. Sequence data after bisulfite treatment indicated that primary cancers and two cell lines with loss of expression were highly methylated compared with nonmalignant colorectal epithelial cells, especially at the attachment sites of primers for MSP, although there was heterogeneity in methylation status. Our results suggest that CDH13 expression is frequently silenced by aberrant methylation in colorectal cancers and adenomas and that methylation of CDH13 commences at an early stage of multistep colorectal tumorigenesis.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
K. Misawa, Y. Ueda, T. Kanazawa, Y. Misawa, I. Jang, J. C. Brenner, T. Ogawa, S. Takebayashi, R. A. Grenman, J. G. Herman, et al.
Epigenetic Inactivation of Galanin Receptor 1 in Head and Neck Cancer
Clin. Cancer Res., December 1, 2008; 14(23): 7604 - 7613.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Suehiro, T. Okada, T. Okada, K. Anno, N. Okayama, K. Ueno, M. Hiura, M. Nakamura, T. Kondo, A. Oga, et al.
Aneuploidy Predicts Outcome in Patients with Endometrial Carcinoma and Is Related to Lack of CDH13 Hypermethylation
Clin. Cancer Res., June 1, 2008; 14(11): 3354 - 3361.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
C. Lofton-Day, F. Model, T. DeVos, R. Tetzner, J. Distler, M. Schuster, X. Song, R. Lesche, V. Liebenberg, M. Ebert, et al.
DNA Methylation Biomarkers for Blood-Based Colorectal Cancer Screening
Clin. Chem., February 1, 2008; 54(2): 414 - 423.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Bai, J. Datta, S. T. Jacob, and K. Ghoshal
Treatment of PC12 Cells with Nerve Growth Factor Induces Proteasomal Degradation of T-cadherin That Requires Tyrosine Phosphorylation of Its Cadherin Domain
J. Biol. Chem., September 14, 2007; 282(37): 27171 - 27180.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
F. Model, N. Osborn, D. Ahlquist, R. Gruetzmann, B. Molnar, F. Sipos, O. Galamb, C. Pilarsky, H.-D. Saeger, Z. Tulassay, et al.
Identification and Validation of Colorectal Neoplasia-Specific Methylation Markers for Accurate Classification of Disease
Mol. Cancer Res., February 1, 2007; 5(2): 153 - 163.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Gratias, H. Rieder, R. Ullmann, L. Klein-Hitpass, S. Schneider, R. Boloni, M. Kappler, and D. R. Lohmann
Allelic Loss in a Minimal Region on Chromosome 16q24 Is Associated with Vitreous Seeding of Retinoblastoma
Cancer Res., January 1, 2007; 67(1): 408 - 416.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
P. Riou, R. Saffroy, C. Chenailler, B. Franc, C. Gentile, E. Rubinstein, T. Resink, B. Debuire, D. Piatier-Tonneau, and A. Lemoine
Expression of T-cadherin in tumor cells influences invasive potential of human hepatocellular carcinoma
FASEB J, November 1, 2006; 20(13): 2291 - 2301.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Shamay, A. Krithivas, J. Zhang, and S. D. Hayward
Recruitment of the de novo DNA methyltransferase Dnmt3a by Kaposi's sarcoma-associated herpesvirus LANA
PNAS, September 26, 2006; 103(39): 14554 - 14559.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Imoto, H. Izumi, S. Yokoi, H. Hosoda, T. Shibata, F. Hosoda, M. Ohki, S. Hirohashi, and J. Inazawa
Frequent Silencing of the Candidate Tumor Suppressor PCDH20 by Epigenetic Mechanism in Non-Small-Cell Lung Cancers.
Cancer Res., May 1, 2006; 66(9): 4617 - 4626.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. M. Lewis, L. R. Cler, D.-W. Bu, S. Zochbauer-Muller, S. Milchgrub, E. Z. Naftalis, A. M. Leitch, J. D. Minna, and D. M. Euhus
Promoter Hypermethylation in Benign Breast Epithelium in Relation to Predicted Breast Cancer Risk
Clin. Cancer Res., January 1, 2005; 11(1): 166 - 172.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
P. Schatz, D. Dietrich, and M. Schuster
Rapid analysis of CpG methylation patterns using RNase T1 cleavage and MALDI-TOF
Nucleic Acids Res., December 2, 2004; 32(21): e167 - e167.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Miotto, S. Sabbioni, A. Veronese, G. A. Calin, S. Gullini, A. Liboni, L. Gramantieri, L. Bolondi, E. Ferrazzi, R. Gafa, et al.
Frequent Aberrant Methylation of the CDH4 Gene Promoter in Human Colorectal and Gastric Cancer
Cancer Res., November 15, 2004; 64(22): 8156 - 8159.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Takahashi, N. Shivapurkar, E. Riquelme, H. Shigematsu, J. Reddy, M. Suzuki, K. Miyajima, X. Zhou, B. N. Bekele, A. F. Gazdar, et al.
Aberrant Promoter Hypermethylation of Multiple Genes in Gallbladder Carcinoma and Chronic Cholecystitis
Clin. Cancer Res., September 15, 2004; 10(18): 6126 - 6133.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Dote, S. Toyooka, K. Tsukuda, M. Yano, M. Ouchida, H. Doihara, M. Suzuki, H. Chen, J.-T. Hsieh, A. F. Gazdar, et al.
Aberrant Promoter Methylation in Human DAB2 Interactive Protein (hDAB2IP) Gene in Breast Cancer
Clin. Cancer Res., March 15, 2004; 10(6): 2082 - 2089.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
L. Kopelovich, J. A. Crowell, and J. R. Fay
The Epigenome as a Target for Cancer Chemoprevention
J Natl Cancer Inst, December 3, 2003; 95(23): 1747 - 1757.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Toyooka, K. O. Toyooka, K. Miyajima, J. L. Reddy, M. Toyota, U. G. Sathyanarayana, A. Padar, M. S. Tockman, S. Lam, N. Shivapurkar, et al.
Epigenetic Down-Regulation of Death-associated Protein Kinase in Lung Cancers
Clin. Cancer Res., August 1, 2003; 9(8): 3034 - 3041.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
U. G. Sathyanarayana, S. Toyooka, A. Padar, T. Takahashi, E. Brambilla, J. D. Minna, and A. F. Gazdar
Epigenetic Inactivation of Laminin-5-encoding Genes in Lung Cancers
Clin. Cancer Res., July 1, 2003; 9(7): 2665 - 2672.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Roman-Gomez, J. A. Castillejo, A. Jimenez, F. Cervantes, C. Boque, L. Hermosin, A. Leon, A. Granena, D. Colomer, A. Heiniger, et al.
Cadherin-13, a Mediator of Calcium-Dependent Cell-Cell Adhesion, Is Silenced by Methylation in Chronic Myeloid Leukemia and Correlates With Pretreatment Risk Profile and Cytogenetic Response to Interferon Alfa
J. Clin. Oncol., April 15, 2003; 21(8): 1472 - 1479.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.